Neurotech (Lincoln, RI) has entered phase II clinical trials for its capsule containing genetically engineered cells for treating retinitis pigmentosa and dry age-related macular degeneration. The treatment, designed to combat the degeneration of light-sensitive cells in the retina, is delivered via a capule implanted in the vitreous humor. The capsule is made of a semipermeable plastic, which allows the protein produced by the genetically engineered cells to diffuse into the retina.
Neurotech’s platform is “unique” and “fills a significant void in treatment options for retinal degenerative diseases,” says Stephen Rose, chief research officer at the nonprofit Foundation Fighting Blindness.
Competitive Technologies Inc. announced that Soteira Inc., has completed a second fund raise for a total of approximately $18 million in Series A and B financing. Massachusetts-based Soteira, a privately-held developer of treatment systems for compressed vertebral fractures, is the exclusive licensee to manufacture, use, and sell products using CTT’s nanoparticle bone biomaterial compound for applications related to the human spine. The funds raised by Soteira will be used for clinical testing of the compound and Soteira’s unique application device.
Advanced Medical Solutions Group Plc reported that its silver anti-microbial wound gel has received FDA for the management of wounds including pressure ulcers, leg ulcers, diabetic ulcers, graft and donor sites, post-operative surgical wounds, trauma wounds, first and second degree burns, and abrasions and lacerations.
